This is a StreetInsider.com Premium Only Page

FibroGen (FGEN) – StreetInsider.com Reports

Apr 9, 2021 03:59 AM Increasing unusual call option volume: FGEN BOX ASO PLNT VIAC

Apr 7, 2021 09:29 AM Pre-Open Stock Movers 04/07: (SOS) (NMTR) (UTME) Higher; (FGEN) (GEO) (FIXX) Lower (more...)

Apr 7, 2021 07:49 AM FibroGen (FGEN) PT Lowered to $55 at Stifel

Apr 7, 2021 06:30 AM Mizuho Securities Downgrades FibroGen (FGEN) to Neutral

Apr 7, 2021 06:11 AM H.C. Wainwright Downgrades FibroGen (FGEN) to Neutral

Apr 6, 2021 07:50 PM FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021

Apr 6, 2021 05:42 PM After-Hours Stock Movers 04/06: (NMTR) (UTME) (NCLH) Higher; (FGEN) (FIXX) (PHR) Lower (more...)

Apr 6, 2021 04:04 PM FibroGen (FGEN) provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from roxadustat Phase 3 program for the treatment of anemia of CKD

Apr 6, 2021 04:01 PM FibroGen Provides Additional Information on Roxadustat

Mar 31, 2021 06:07 AM BofA Securities Upgrades FibroGen (FGEN) to Buy

Mar 16, 2021 07:08 AM FibroGen (FGEN) Begins LELANTOS-2, a Second Phase 3 Clinical Study of Pamrevlumab for Treatment of DMD

Mar 16, 2021 07:00 AM FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

Mar 2, 2021 09:28 AM Pre-Open Stock Movers 03/02: (INUV) (TMDX) (RKT) Higher; (FGEN) (LODE) (AI) Lower (more...)

Mar 2, 2021 06:53 AM UPDATE: Jefferies Downgrades FibroGen (FGEN) to Hold

Mar 1, 2021 05:35 PM After-Hours Stock Movers 03/01: (ZM) (PSN) (NLSN) Higher; (FGEN) (AI) (INSG) Lower (more...)

Mar 1, 2021 04:06 PM FibroGen (FGEN) announces FDA will hold an advisory committee meeting to review the new drug application for roxadustat

Mar 1, 2021 04:01 PM FibroGen Provides Regulatory Update on Roxadustat

Mar 1, 2021 04:01 PM FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 18, 2021 07:00 AM FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results

Feb 12, 2021 07:00 AM FibroGen to Present at Upcoming Investor Conferences

Feb 10, 2021 03:57 PM FibroGen (FGEN), Pliant Therapeutics (PLRX) to Benefit from Galapagos (GLPG)/Gilead (GILD) Discontinued ISABELA Phase 3 Trials in IPF - Citi

Feb 1, 2021 06:32 AM UPDATE: H.C. Wainwright Starts FibroGen (FGEN) at Buy

Dec 22, 2020 07:02 AM FibroGen (FGEN) Reports First Patient Dosing in ZEPHYRUS-2 Phase 3 Clinical Study of Pamrevlumab in Patients with IPF

Dec 22, 2020 07:00 AM FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

Dec 21, 2020 06:56 AM Mizuho Securities Reiterates Buy Rating on FibroGen (FGEN)

Dec 18, 2020 04:59 PM FibroGen Provides Regulatory Update on Roxadustat

Dec 14, 2020 08:06 AM FibroGen (FGEN) PT Lowered to $70 at Stifel

Dec 2, 2020 07:06 AM FibroGen (FGEN) to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at ASH

Dec 2, 2020 07:00 AM FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting

Dec 1, 2020 08:00 AM FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Nov 27, 2020 07:01 AM FibroGen (FGEN) Receives Approval of EVRENZO in Japan for Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Nov 27, 2020 07:00 AM Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Nov 27, 2020 06:00 AM FibroGen (FGEN), Astellas Pharma Inc. Granted Approval of EVRENZO (roxadustat) in Japan for Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Nov 27, 2020 02:02 AM Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Nov 6, 2020 07:00 AM FibroGen to Present at Upcoming Investor Conferences

Nov 5, 2020 04:01 PM FibroGen Reports Third Quarter 2020 Financial Results

Oct 29, 2020 07:00 AM FibroGen to Report Third Quarter 2020 Financial Results

Oct 26, 2020 07:21 AM UPDATE: Raymond James Starts FibroGen (FGEN) at Underperform

Oct 23, 2020 06:57 AM FibroGen (FGEN) Steals the Show at ASN, Bodes Well for Upcoming PDUFA - Stifel

Oct 22, 2020 10:08 AM FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)

Oct 14, 2020 07:08 AM FibroGen (FGEN) to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week

Oct 14, 2020 07:00 AM FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined

Oct 2, 2020 07:00 AM New Ventures Funds Rebrands as Scientia Ventures

Sep 8, 2020 07:00 AM FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

Sep 3, 2020 08:56 AM Pre-Open Stock Movers 9/03: (KCAC) (FGEN) (FIVE) (NVAX) (AKBA) (CIEN) (TSLA) (More...)

Sep 1, 2020 07:00 AM FibroGen to Present at Upcoming Investor Conferences

Aug 11, 2020 07:14 AM FibroGen (FGEN) Reports First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

Aug 11, 2020 07:00 AM FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

Aug 6, 2020 04:02 PM FibroGen Reports Second Quarter 2020 Financial Results

Aug 6, 2020 04:01 PM FibroGen Announces New Appointments to its Board of Directors